Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label
tabling member	label

Search

1019268

	registered interest
	date	03/12/2018
	answering body	Department for Digital, Culture, Media and Sport
	answering dept id	10
	answering dept short name	Digital, Culture, Media and Sport
	answering dept sort name	Digital, Culture, Media and Sport
	hansard heading	Gambling: Video Games
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans, if any, they have to conduct an investigation into the impact loot boxes in video games have on (1) underage gambling, and (2) instances of gambling related harm.
	tabling member printed	Lord Chadlington
	uin	HL11957
	answer	answer is ministerial correction date of answer 17/12/2018 answer text <p>Where gambling facilities are offered, operators must have a licence from the Gambling Commission and have controls in place to prevent underage gambling.</p><p> </p><p>Loot boxes do not fall under gambling law where the in-game items acquired are confined for use within the game and cannot be cashed out. However, the Government is aware of concerns that loot boxes and other entertainment products, such as some video games, could encourage gambling-like behaviour and longer term lead to gambling related harm, and will continue to look closely at any evidence around this issue. We welcome the recent introduction by the VSC Ratings Board and PEGI of a new label for video games to warn parents where they include the opportunity to make in-game purchases.</p><p> </p><p>In September 2018, the Gambling Commission, along with 16 other regulators from Europe and the USA signed a declaration which outlined common concerns around gaming and gambling. The regulators agreed to work together to monitor the characteristics of video games and social gaming and where there is potential cross-over into gambling.</p> answering member printed Viscount Younger of Leckie question first answered 17/12/2018 17:58:31 answering member 4169 label Biography information for Viscount Younger of Leckie
	tabling member	3318 label Biography information for Lord Chadlington

1019302

	registered interest
	date	03/12/2018
	answering body	Department for Digital, Culture, Media and Sport
	answering dept id	10
	answering dept short name	Digital, Culture, Media and Sport
	answering dept sort name	Digital, Culture, Media and Sport
	hansard heading	Social Media
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they have any plans to invest in cyber skills to help improve the digital protection provided to users of social media.
	tabling member printed	Lord Taylor of Warwick
	uin	HL11991
	answer	answer is ministerial correction date of answer 17/12/2018 answer text <p>Our Digital Charter aims to make the UK the safest place in the world to be online. As part of this work, we will publish an Online Harms White Paper in winter 2018/19, which will include a range of proposals including setting out how we will ensure that parents, children and other users develop the skills they need to stay safe online.</p><p> </p><p>Government is committed to increasing cyber security capacity across all sectors to ensure that the UK has the right level and blend of skills required to maintain our resilience to cyber threats and be the world’s leading digital economy.</p> answering member printed Viscount Younger of Leckie question first answered 17/12/2018 17:58:46 answering member 4169 label Biography information for Viscount Younger of Leckie
	tabling member	1796 label Biography information for Lord Taylor of Warwick

1019277

	registered interest
	date	03/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to expand the range of drugs covered by the New Medicines Scheme in community pharmacies.
	tabling member printed	Baroness Jolly
	uin	HL11966
	answer	answer is ministerial correction date of answer 17/12/2018 answer text <p>There are no current plans to expand the New Medicine Service. All changes to the community pharmacy contractual framework are made following negotiations with the Pharmaceutical Services Negotiating Committee.</p> answering member printed Lord O'Shaughnessy question first answered 17/12/2018 13:03:35 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4203 label Biography information for Baroness Jolly

1019278

	registered interest
	date	03/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what impact assessment they have carried out on the possible decommissioning of the Minor Ailments Scheme.
	tabling member printed	Baroness Jolly
	uin	HL11967
	answer	answer is ministerial correction date of answer 17/12/2018 answer text <p>No assessment of the impact of decommissioning of local Minor Ailment Schemes (MAS) has been undertaken nationally. MASs are currently commissioned locally by the National Health Service according to need. A pilot digital minor illness referral service (DMIRS) commenced last year in the North East with direct referrals from NHS 111 to community pharmacy. Building on this three further DMIRS pilots, supported by the Pharmacy Integration Fund, were launched in November 2018, in Devon, London and East Midlands. An evaluation will inform next steps.</p> answering member printed Lord O'Shaughnessy question first answered 17/12/2018 13:03:05 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4203 label Biography information for Baroness Jolly

1019279

	registered interest
	date	03/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to expand the number of prescribing pharmacists.
	tabling member printed	Baroness Jolly
	uin	HL11968
	answer	answer is ministerial correction date of answer 17/12/2018 answer text <p>Pharmacists prescribers are currently working across a range of services in both secondary and primary care. As part of a planned programme of expansion, additional pharmacists are being recruited to work in patient facing roles in general practice. They will be treating patients using their expert knowledge of medicines for specific disease areas and they will either be prescribers, or training to become one. As of October 2018, 876 clinical pharmacists have been recruited, and we have been informed by NHS England that it is committed to recruiting an additional 1,950 clinical pharmacists in general practice by 2020/21.</p> answering member printed Lord O'Shaughnessy question first answered 17/12/2018 13:03:22 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4203 label Biography information for Baroness Jolly

1019280

	registered interest
	date	03/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy Integration Fund
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how the Pharmacy Integration Fund has been spent; and what plans they have for the future of the fund.
	tabling member printed	Baroness Jolly
	uin	HL11969
	answer	answer is ministerial correction date of answer 17/12/2018 answer text <p>The Pharmacy Integration Fund (PhIF) has been used to support the employment of pharmacists in integrated urgent care, general practice and care homes where their expert knowledge of medicines is helping to ensure the best care for patients. It has also been used to fund pilots of the supply of urgent medicines to patients without the need for a general practitioner appointment as well as the referral of patients, presenting with minor illness, direct from NHS111 or NHS Online to community pharmacy. These programmes are aimed at better utilising the skillset and reach of community pharmacy teams to support the wider health service. They are being underpinned by several new education and leadership programmes which are also being funded by the PhIF.</p><p>The Government remains committed to this programme and we are continuing to invest in the development of community pharmacy through this fund. Most recently, NHS England announced their plans for a new pilot scheme, with investment of £1 million from the PhIF, to develop system leadership within pharmacy. These pharmacy leaders will set the vision for pharmacy and medicines optimisation within their area, and will support the delivery of a NHS Pharmacy and Medicines Optimisation Transformation Plan, making the best use of pharmacy in meeting local and national health priorities.</p> answering member printed Lord O'Shaughnessy question first answered 17/12/2018 13:02:49 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4203 label Biography information for Baroness Jolly

1019281

	registered interest
	date	03/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Counterfeit Manufacturing
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to protect patients from counterfeit medicines if the Falsified Medicines Directive ceases to apply in the UK after Brexit.
	tabling member printed	Baroness Jolly
	uin	HL11970
	answer	answer is ministerial correction date of answer 13/12/2018 answer text <p>In the United Kingdom, strict regulatory controls govern the sale, supply, manufacture, distribution and advertising of medicinal products. Although no fatalities in the UK have been attributed to a falsified medicine sourced from the UK regulated supply chain, the potential threat to patient health is recognised and taken seriously across Government.</p><p>The European Union Falsified Medicines Directive (FMD) was adopted in 2011 and introduced new harmonised measures to ensure that medicines in the EU are safe and that trade in medicines is properly controlled.</p><p>The parts of the Directive that have already been implemented – including tougher rules on the control and inspection of producers of active pharmaceutical ingredients – would be converted into UK law through the Withdrawal Act and therefore remain in place after exit.</p><p>The final element of the Directive – the Delegated Regulation for new safety features – is due to come into force in February 2019, including the creation of a central EU data hub. The UK will still be a Member State in February 2019 and will therefore implement the FMD Delegated Regulation in line with our existing obligations.</p><p>In terms of what would happens after the UK exits the EU, during an implementation period the UK would maintain the new safety features and retain access to the EU central data hub, with arrangements beyond the implementation period still subject to negotiation. In the unlikely event the UK leaves the EU in March 2019 with no deal in place, then as stated in the Medicines and Healthcare products Regulatory Agency recent No Deal consultation, we expect the UK would not have access to the EU central data hub, and therefore the proposal is that legal obligations related to this would be removed for actors in the UK supply chain. In the interests of public safety, we would then evaluate the options around a future national falsified medicines framework.</p><p>Whatever the exit scenario, we will continue to ensure that UK patients are able to access the best and most innovative medicines and that their safety is protected.</p> answering member printed Lord O'Shaughnessy question first answered 13/12/2018 15:19:02 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4203 label Biography information for Baroness Jolly

1019282

	registered interest
	date	03/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many pharmaceutical manufacturers have guaranteed to hold six weeks' supply of their medicines for the next six months on top of their buffer stocks; and what proportion of pharmaceutical medicines used in the UK are now covered by that guarantee.
	tabling member printed	Baroness Jolly
	uin	HL11971
	answer	answer is ministerial correction date of answer 13/12/2018 answer text <p>The Government has agreed the terms of our exit from the European Union, as set out in the Withdrawal Agreement. The Withdrawal Agreement offers a time-limited implementation period that provides a bridge to the future relationship, allowing business, including the life sciences industry, to continue trading as now until the end of 2020. The supply of medicines and medical supplies would remain unchanged during the implementation period.</p><p>As a responsible Government, however, we continue to prepare proportionately for all scenarios, including the unlikely outcome that we leave the EU without any deal in March 2019.</p><p>On 23 August 2018, the Department asked suppliers of all prescription-only and pharmacy medicines with an EU/European Economic Area touch point to confirm their contingency arrangements for continued supply to United Kingdom patients beyond 29 March 2019 in the event of a no-deal Brexit and possible delays at the border in the following period.</p><p>To date we have received very good engagement from industry, who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit. However, as our engagement exercise is still on-going we do not yet have final figures to report.</p> answering member printed Lord O'Shaughnessy question first answered 13/12/2018 15:20:24 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4203 label Biography information for Baroness Jolly

1019290

	registered interest
	date	03/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 5 November (HL10893), what is the average cost to the NHS of treating patients with (1) leukaemia, (2) non-hodgkin lymphoma, (3) hodgkin lymphoma, and (4) myeloma.
	tabling member printed	Lord Mendelsohn
	uin	HL11979
	answer	answer is ministerial correction date of answer 13/12/2018 answer text <p>The data is not collected in the format requested.</p> answering member printed Lord O'Shaughnessy question first answered 13/12/2018 15:17:35 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4286 label Biography information for Lord Mendelsohn

1019270

	registered interest
	date	03/12/2018
	answering body	The Senior Deputy Speaker
	answering dept id	204
	answering dept short name
	answering dept sort name	Senior Deputy Speaker (HoL)
	hansard heading	Bills: Parliamentary Scrutiny
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask the Senior Deputy Speaker, further to the Government’s response to the report of the Constitution Committee, Parliament and the Legislative Process, published on 20 April 2005 (HL Paper 114), whether the Procedure Committee will consider the recommendation that bills should normally be committed after Second Reading to a committee empowered to take evidence.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL11959
	answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>In 2005, when it responded to the Constitution Committee’s report, Parliament and the Legislative Process, the Government was “not convinced that it would be appropriate to commit all bills which have not been scrutinised in draft to an evidence-taking committee after Second Reading but we are ready to consider this option in exceptional circumstances (and have done in the past).” <br> <br>I am aware that the idea that bills should normally be committed after Second Reading to a committee empowered to take evidence is under fresh consideration by the Constitution Committee as part of its current inquiry on the legislative process, stage 2 of which is covering the passage of legislation through Parliament. Written and oral evidence received as part of that inquiry is available here - https://www.parliament.uk/business/committees/committees-a-z/lords-select/constitution-committee/inquiries/parliament-2017/legislative-process/. I am looking forward to the Committee’s report and any recommendations it might make on this and other matters. The Procedure Committee will give it due consideration then.</p> answering member printed Lord McFall of Alcluith question first answered 18/12/2018 12:58:07 answering member 4148 label Biography information for Lord McFall of Alcluith
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath